Display options
Cite
Jeong SU, Kekatpure AK, Park JM, et al. Diverse Immunoprofile of Ductal Adenocarcinoma of the Prostate with an Emphasis on the Prognostic Factors. J Pathol Transl Med. 2017;51(5):471-481doi: 10.4132/jptm.2017.06.02.
Jeong, S. U., Kekatpure, A. K., Park, J. M., Han, M., Hwang, H. S., Jeong, H. J., Go, H., & Cho, Y. M. (2017). Diverse Immunoprofile of Ductal Adenocarcinoma of the Prostate with an Emphasis on the Prognostic Factors. Journal of pathology and translational medicine, 51(5), 471-481. https://doi.org/10.4132/jptm.2017.06.02
Jeong, Se Un, et al. "Diverse Immunoprofile of Ductal Adenocarcinoma of the Prostate with an Emphasis on the Prognostic Factors." Journal of pathology and translational medicine vol. 51,5 (2017): 471-481. doi: https://doi.org/10.4132/jptm.2017.06.02
Jeong SU, Kekatpure AK, Park JM, Han M, Hwang HS, Jeong HJ, Go H, Cho YM. Diverse Immunoprofile of Ductal Adenocarcinoma of the Prostate with an Emphasis on the Prognostic Factors. J Pathol Transl Med. 2017 Sep;51(5):471-481. doi: 10.4132/jptm.2017.06.02. Epub 2017 Aug 09. PMID: 28793393; PMCID: PMC5611530.
Copy Download .nbib Format: NLM
Share it on

J Pathol Transl Med. 2017 Sep;51(5):471-481. doi: 10.4132/jptm.2017.06.02. Epub 2017 Aug 09.

Diverse Immunoprofile of Ductal Adenocarcinoma of the Prostate with an Emphasis on the Prognostic Factors.

Journal of pathology and translational medicine

Se Un Jeong, Anuja Kashikar Kekatpure, Ja-Min Park, Minkyu Han, Hee Sang Hwang, Hui Jeong Jeong, Heounjeong Go, Yong Mee Cho

Affiliations

  1. Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  2. Asan Institute for Life Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  3. Department of Clinical Epidemiology and Biostatistics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

PMID: 28793393 PMCID: PMC5611530 DOI: 10.4132/jptm.2017.06.02

Abstract

BACKGROUND: Ductal adenocarcinoma (DAC) of the prostate is an uncommon histologic subtype whose prognostic factors and immunoprofile have not been fully defined.

METHODS: To define its prognostic factors and immunoprofile, the clinicopathological features, including biochemical recurrence (BCR), of 61 cases of DAC were analyzed. Immunohistochemistry was performed on tissue microarray constructs to assess the expression of prostate cancer-related and mammalian target of rapamycin (mTOR) signaling-related proteins.

RESULTS: During the median follow-up period of 19.3 months, BCR occurred in 26 cases (42.6%). DAC demonstrated a wide expression range of prostate cancer-related proteins, including nine cases (14.8%) that were totally negative for pan-cytokeratin (PanCK) immunostaining. The mTOR signaling-related proteins also showed diverse expression. On univariate analysis, BCR was associated with high preoperative serum levels of prostate-specific antigen (PSA), large tumor volume, predominant ductal component, high Gleason score (GS), comedo-necrosis, high tumor stage (pT), lymphovascular invasion, and positive surgical margin. High expressions of phospho-mTOR (p-mTOR) as well as low expressions of PSA, phospho-S6 ribosomal protein (pS6) and PanCK were associated with BCR. On multivariable analysis, GS, pT, and immunohistochemical expressions of PanCK and p-mTOR remained independent prognostic factors for BCR.

CONCLUSIONS: These results suggest GS, pT, and immunohistochemical expressions of PanCK and p-mTOR as independent prognostic factors for BCR in DAC. Since DAC showed diverse expression of prostate cancer-related proteins, this should be recognized in interpreting the immunoprofile of DAC. The diverse expression of mTOR-related proteins implicates their potential utility as predictive markers for mTOR targeted therapy.

Keywords: Carcinoma, ductal; Immunohistochemistry; Prognosis; Prostatic neoplasms

References

  1. Cancer Res. 2001 Jan 15;61(2):423-7 - PubMed
  2. Am J Clin Pathol. 2002 Apr;117(4):552-7 - PubMed
  3. Int J Urol. 2004 Sep;11(9):805-8 - PubMed
  4. J Clin Oncol. 2006 Jan 10;24(2):268-73 - PubMed
  5. Am J Clin Pathol. 2006 Aug;126(2):302-9 - PubMed
  6. Nat Rev Cancer. 2006 Sep;6(9):729-34 - PubMed
  7. Eur Urol. 2007 Aug;52(2):455-63 - PubMed
  8. Mod Pathol. 2008 Nov;21(11):1371-8 - PubMed
  9. Ann Diagn Pathol. 2008 Aug;12(4):260-6 - PubMed
  10. Trends Cell Biol. 2009 Jan;19(1):16-23 - PubMed
  11. Cancer. 2009 Jul 1;115(13):2872-80 - PubMed
  12. Mod Pathol. 2009 Oct;22(10):1273-9 - PubMed
  13. Ann Surg Oncol. 2010 Jun;17(6):1471-4 - PubMed
  14. Urology. 2010 Nov;76(5):1268.e7-13 - PubMed
  15. BJU Int. 2012 Mar;109(6):831-4 - PubMed
  16. Cell. 2012 Apr 13;149(2):274-93 - PubMed
  17. APMIS. 2012 Jun;120(6):510-8 - PubMed
  18. Korean J Pathol. 2012 Oct;46(5):423-8 - PubMed
  19. Eur Urol. 2013 Jul;64(1):150-8 - PubMed
  20. Appl Immunohistochem Mol Morphol. 2014 Oct;22(9):652-7 - PubMed
  21. Am J Surg Pathol. 2014 Aug;38(8):e6-e19 - PubMed
  22. Biochim Biophys Acta. 2014 Dec;1846(2):638-54 - PubMed
  23. Prostate. 2015 Oct;75(14):1610-9 - PubMed
  24. Urology. 2015 Dec;86(6):1206-11 - PubMed
  25. APMIS. 2016 Apr;124(4):263-70 - PubMed
  26. Eur Urol. 2016 Jul;70(1):106-119 - PubMed
  27. Target Oncol. 2017 Feb;12(1):47-59 - PubMed
  28. Adv Anat Pathol. 2017 Jan;24(1):35-44 - PubMed
  29. Semin Diagn Pathol. 1988 Aug;5(3):301-11 - PubMed
  30. Am J Surg Pathol. 1985 Aug;9(8):595-609 - PubMed
  31. Cancer. 1967 Oct;20(10):1715-22 - PubMed
  32. J Surg Oncol. 1994 Apr;55(4):235-8 - PubMed
  33. Am J Pathol. 1994 Apr;144(4):735-46 - PubMed
  34. Br J Cancer. 1994 May;69(5):924-30 - PubMed
  35. Histopathology. 1996 Jul;29(1):11-9 - PubMed
  36. Br J Urol. 1998 Jan;81(1):109-15 - PubMed

Publication Types